Abstract. Re-education of tumor-associated macrophages (TAMs) toward antitumor effectors may be a promising therapeutic strategy for the successful treatment of cancer. HangAmDan-B (HAD-B), a herbal formula, has been used for stimulating immune function and activation of vital energy to cancer patients in traditional Korean Medicine. Previous studies have reported the anti-angiogenic and anti-metastatic effects of HAD-B; however, evidence on the immunomodulatory action of HAD-B was not demonstrated. In the present study, immunocompetent mice were used to demonstrate the suppression of the in vivo growth of allograft Lewis lung carcinoma (LLC) cells, by HAD-B. In addition, HAD-B inhibited the in vitro growth of LLC cells by driving macrophages toward M1 polarization, but not through direct inhibition of tumor cell growth. Furthermore, culture media transfer of HAD-B-treated macrophages induced apoptosis of LLC cells. Results of the present study suggest that the antitumor effect of HAD-B may be explained by stimulating the antitumor function of macrophages. Considering the importance of re-educating TAMs in the regulation of the tumor microenvironment, the present study may confer another option for anti-cancer therapeutic strategy, using herbal medicines such as HAD-B.
Introduction
The intercommunication between a tumor and its microenvironment (including stromal cells and the extracellular matrix) contributes to multiple stages of cancer progression, particularly local resistance, immune-escape and metastasis (1, 2) . Macrophages are a major stromal component within the tumor region, termed tumor associated macrophages (TAMs), and can promote tumor progression by changing the phenotype of the tumor (3) . In general, TAMs are functionally similar to alternatively activated (M2) polarization, which exerts anti-inflammatory and pro-tumorigenic activities. By contrast, classically activated (M1 polarization) macrophages act as immune-stimulatory and antitumor effectors (1, 4) . Thus, depletion of TAMs or their re-education toward antitumor effectors is considered a promising therapeutic strategy for the successful treatment of cancer (5, 6) .
HangAmDan-B (HAD-B), a Korean medicinal herbal formula, consisting of eight ingredient medicinal animals and plants, has been used for the treatment of cancer patients in the clinic to stimulate immune function and activation of vital energy (7) . Previous studies have reported the anti-angiogenic and anti-metastatic effects of HAD-B (7, 8) . In addition, the suppression of γ-aminobutyric acid B receptor 1 (GABABR1) and heat shock protein 27 (HSP27) expression was demonstrated as a molecular mechanism underlying the anti-cancer effect of HAD-B (9, 10) . However, previous studies have not provided evidence on the immunomodulatory action of HAD-B.
The present study demonstrated that HAD-B reduced the growth of Lewis lung carcinoma (LLC) in an allograft mouse model, using immunocompetent mice. The results from in vitro experiments demonstrated that the inhibition of cancer growth is mediated by regulating macrophage shape towards M1. These results suggest that the antitumor effect of HAD-B may be explained by stimulating antitumor function of macrophages. Preparation of HAD-B. HAD-B, composed of eight herbal ingredients in a crude ground power form (Table I) , was obtained from the East-West Cancer Center of Dunsan Korean Hospital (Daejeon, Korea). The water extract of HAD-B was prepared as previously reported (7) . Briefly, crude powder of HAD-B was extracted with 10 times (v/w) the amount of distilled water, at room temperature for 24 h. The sample was centrifuged at 1,000 x g for 30 min, filtered and lyophilized. The extracted powder was dissolved in distilled water to make a concentration of 100 mg/ml, and sterilized with a 0.2 µm syringe filter. The stock solutions were stored at -80˚C until use, and diluted with PBS or culture medium prior to use in the experiments.
Materials and methods

Materials
Animals. Male C57BL/6 mice (six-week-old; weight, 20-24 g) were purchased from Orient Bio Inc. (Sungnam, Korea). The animals were all housed in certified laboratory chambers, maintained at a constant temperature (22±1˚C), humidity (50±5%), and 12 h dark/light cycles. The mice had free access to a standard diet and drinking water prior to the experiment. The morphology of cultured RAW 264.7 cells was observed using inverted optical microscopy (magnification, x200; Nikon ECLIPSE TS100, Tokyo, Japan).
Tumor allograft model. Separated LLC cells (5x10 5 cells) were suspended in 100 µl of PBS and injected into the subcutaneous dorsa of 7-week-old C57BL/6 mice. One day after the tumor cell inoculation, the mice in the control group were administered daily with 100 µl of PBS orally, for 21 days. The mice in the HAD-B-treated group were orally administrated with HAD-B (2 mg in 100 µl PBS/20 g mouse) per day, for 21 days. Tumor volumes were measured with a pair of calipers at 14, 17 and 21 days. The volumes were calculated according to the formula [(1x w 2 )/2], where l and w stand for length and width, respectively. At the end of the experiment, all mice were sacrificed by inhalation of CO 2 gas and the tumor specimens were immediately removed and weighed.
Cell viability assay. Cytotoxic effects caused by HAD-B treatment or culture medium of HAD-B-treated RAW 264.7 cells were measured using a MTT assay. Briefly, LLC or RAW 264.7 cells were incubated in 24-well plates with indicated concentrations of HAD-B (0, 100, 500 and 1,000 µg/ml). After culture for 24 or 48 h, MTT solution (2.0 mg/ml) was added and incubated at 37˚C and 5% CO 2 for 4 h. The conditioned media were removed, and formazan crystals, which formed in live cells, were measured by absorbance at 540 nm, using a microplate reader (Spectramax M2; Molecular Devices, LCC., Sunnyvale, CA, USA).
Reverse-transcription polymerase chain reaction (RT-PCR).
Total RNAs were extracted from cells using the GeneJET RNA purification kit (Thermo Fisher Scientific, Inc.). Equal amounts of total RNA (2 µg) were applied for synthesizing cDNA using oligo-dT primer and AccuPower RT-PreMix (Bioneer Co., Daejeon, Korea). Western blot analysis. Total protein was extracted from cells using radioimmunoprecipitation assay buffer (Cell Signaling Technology, Inc.) containing 1 mM phenylmethylsulfonyl fluoride. The amount of protein was estimated using the Quick Start™ Bradford Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA). An equal amount (20 µg) of protein from each sample was separated by SDS-PAGE and the protein was blotted onto a nitrocellulose membrane (Hybond ECL; GE Healthcare Life Sciences, Uppsala, Sweden) by electrophoresis. The transferred membrane was blocked for 1 h with 5% non-fat dry milk at room temperature and incubated with anti-caspase-3 and PARP primary antibodies (both 1:200) against the target protein at 4˚C overnight. The membranes were washed 3 times in TBS-Tween-20) and blocked using 5% skimmed milk and incubated overnight at 4˚C. The membranes were subsequently probed with goat anti-rabbit Immunoglobulin G horseradish peroxidase-conjugated secondary antibody (1:2,000; cat. no. NCI1460KR; Thermo Fisher Scientific, Inc.) for 1 h at room temperature. The specific bands of proteins of interest were detected using ECL Plus (GE Healthcare Life Sciences) and ImageQuant LAS 4000 (GE Healthcare Life Sciences).
Statistical analysis.
Cell viability results were calculated by the percentage of control cells and expressed as the mean ± standard deviation. The differences of the mean values compared with the control groups were evaluated using two-way analysis of variance with the Bonferroni post hoc test for multiple comparisons, and the Student's t-test for single comparisons. The minimum level of significance was set at P<0.05 for all the analyses. All experiments were performed independently at least three times. 79; Fig. 1A) . The weight and size of removed tumor mass from each group was also reduced by HAD-B treatment (Fig. 1B and C) . These results demonstrated that HAD-B suppressed the growth of LLC cells in the in vivo mouse model.
Results
HAD-B suppressed growth of LLC cells in an in
HAD-B reduced growth of LLC cells in a macrophage-dependent manner.
The in vitro antitumor activity of HAD-B on LLC cells was then confirmed. However, notably, the growth of HAD-B was not suppressed by HAD-B treatment ( Fig. 2A) . Therefore, the in vivo antitumor effect of HAD-B involved with regulation of macrophages was examined. HAD-B had no cytotoxic effect on LLC cells up to the concentration of 1,000 µg/ml (Fig. 2B) . To determine whether the antitumor effect of HAD-B is mediated by macrophages, culture media was transferred from RAW 264.7 cells to LLC cells. The growth rates of LLC cells were significantly reduced by adding the culture media from RAW 264.7 cell, treated with HAD-B in a dose-dependent manner (100 µg/ml, P<0.01; 500 µg/ml, P<0.001). At 48 h culture, following transfer of media from RAW 264.7 cells treated with 100 and 500 µg/ml, the growth of LLC cells was reduced to 65 and 44.5%, respectively, compared with the control (Fig. 2C) . From these results, it is suggested that in vivo antitumor action of HAD-B may be mediated by regulation of macrophages, but is not due to the direct cytotoxic effect of HAD-B on LLC cells.
HAD-B shift macrophages phenotype toward M1. Results from RT-PCR analysis demonstrated that HAD-B increased
the expression of M1 markers, including iNOS, IL-1β, MCP-1 and TNF-α, in a dose-dependent manner. By contrast, representative M2 markers, including arginase-1 and YM, were not changed by HAD-B treatment. However, the expression of CD206, a marker of alternative polarization, was reduced by HAD-B treatment (Fig. 3A) . In addition, HAD-B changed the morphology of RAW 264.7 cells toward the shape of a classically activated macrophage (Fig. 3B) . Results from the present study demonstrated that HAD-B drives macrophages toward a tumor-inhibitory M1 phenotype. Thus, M1 polarization of macrophages induced by HAD-B treatment may be a cause of macrophage-mediated suppression of tumor growth.
HAD-B treated macrophage culture media induces apoptosis of LLC cells.
To evaluate whether macrophage-mediated death of LLC is apoptosis, FACS analysis was performed using Annexin V-FITC staining. The result demonstrated that the (Fig. 4A) . The results showed an association between the data from the cell viability assay and changes in the macrophage phenotype. The apoptosis pathways that are activated by culture media from HAD-B-treated RAW 264.7 cells were then confirmed. The results from western blot analysis showed activation of caspase-3 and cleavage of PARP (Fig. 4B) . These results suggested that HAD-B-treated cell culture media induce the apoptosis of LLC through a macrophage-dependent pathway.
Discussion
Previously, antitumor effects of HAD-B were investigated in several in vitro models (7) (8) (9) (10) . However, to the best of our knowledge, there is no preceding report on the in vivo antitumor effect of HAD-B. Thus, the present study examined in vivo antitumor activity of HAD-B using an immunocompetent mouse allograft model. The results from the present study demonstrated that HAD-B suppressed the growth of allograft LLC cells. However, HAD-B did not affect the growth of LLC cells in the in vitro assay. Since HAD-B has been used for stimulating immune function of cancer patients in the clinic (7), it was supposed that HAD-B may control the growth of tumor cells through the regulation of immune cells present in the tumor microenvironment. Among these immune cells, macrophages are a major cellular component within the tumor region (3). Thus, the possibility that the antitumor effect of HAD-B is mediated by macrophages was examined. When the culture media from HAD-B-treated RAW 264.7 macrophage cells were transferred to LLC cells, the growth rates of LLC cells were reduced.
Macrophages polarize toward two major phenotypes: Classically activated (M1) and alternatively activated (M2).
In the majority of cancers, tumor-associated macrophages (TAMs) were polarized to M2 phenotype (11, 12) , which serve anti-inflammatory and pro-tumorigenic actions (13) . By contrast, M1 macrophages possess high antitumor and immune-stimulatory functions through the production of pro-inflammatory factors and the expression of major histocompatibility complex (MHC) class I and class II molecules (14) . Thus, re-education of M2-like TAMs toward a M1 phenotype is regarded as a beneficial strategy for the treatment of cancer (15, 16) . In the present study, HAD-B drove RAW 264.7 macrophage cells to polarize toward an antitumorigenic M1 type.
Macrophages re-educated toward M1 suppress the growth of tumor cells through diverse pathways, including secretion of pro-inflammatory cytokines, production of reactive nitrogen and oxygen intermediates, promotion of Th1 response and tumoricidal activity (6, 13) . When culture media from THP-1-derived M1 macrophages was added to several human cancer cell lines, including HT-29 and CACO-2, the growth of tumor cells was reduced by the induction of apoptosis and retardation of cell cycles (17, 18) . In addition, co-culture of M1 macrophages increased the etoposide induced apoptosis in HepG2 human hepatocellular carcinoma cells and A549 human lung cancer cells (19) . Previous studies revealed that M1 macrophages exhibit direct cytotoxic activity on tumor cells. It is hypothesized that the direct antitumor action of M1 macrophages is mediated by soluble factors, including pro-inflammatory cytokines and reactive nitrogen/oxygen intermediates (13, 18, 20) . In agreement with previous studies, the results from the present study demonstrated that HAD-B induces apoptosis of LLC cells in a macrophage-dependent manner.
Functional reprogramming of TAMs is regarded as a promising therapeutic strategy for cancer inhibition (4,15). Cancer cells are capable of educating macrophages into a M2 phenotype, which possess anti-inflammatory and pro-tumorigenic effects. In addition, a high density of M2 showed positive correlation with prognostic factors, including size, stage, metastasis, and histological grade of the tumor (21, 22) . Thus, a number of studies are focused on regulating macrophage polarization through inhibiting recruitment of monocytes and depletion of monocyte/macrophage lineages by treating chemotherapeutic agents, including cisplatin, 5-fluorouracil, and docetaxel, low-dose ionized radiation, and neutralizing antibodies for cytokines, including CD40 and colony stimulating factor-1 (6,13). However, these strategies are not ideal, since recruited macrophages can be used to enhance the immune response or to potentiate chemotherapy specificity (23) . Suppression of tumor growth can also be achieved by functionally re-educating TAMs, rather than by eradiating them. Thus, to switch macrophages to M1, several small molecule inhibitors against STAT3, STAT6, p50 subunit of NF-κB and IKKβ are now being developed (13) .
In the present study, results demonstrated that HAD-B can suppress the growth of LLC cells through driving macrophages toward M1 polarization, but not direct inhibition of tumor cell growth. In vivo experiments also showed inhibition of allograft LLC cells using immunocompetent mice (Fig. 5) . In addition to previously reported anti-angiogenic (24) and anti-metastatic (7) effects, results from the present study suggest that the anti-cancer effect of HAD-B may be due to re-education of macrophages toward the M1 phenotype. To the best of our knowledge, this is the first experimental evidence of the immunomodulatory action of HAD-B. To elucidate which ingredient herbs or compounds are responsible for switching macrophage phenotype, more extensive studies are required. Considering the importance of re-educating TAMs in the regulation of tumor microenvironment, the present study may confer another option for anti-cancer therapeutic strategy using herbal medicine including HAD-B. 
